针刺影响房颤患者生活质量的随机对照临床研究

注册号:

Registration number:

ITMCTR2100005111

最近更新日期:

Date of Last Refreshed on:

2021-07-30

注册时间:

Date of Registration:

2021-07-30

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刺影响房颤患者生活质量的随机对照临床研究

Public title:

Effect of Acupuncture on Quality of Life in Patients With Atrial Fibrillation: A Randomized Controlled Trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺影响房颤患者生活质量的随机对照临床研究

Scientific title:

Effect of Acupuncture on Quality of Life in Patients With Atrial Fibrillation: A Randomized Controlled Trial

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100049323 ; ChiMCTR2100005111

申请注册联系人:

林滢

研究负责人:

刘存志

Applicant:

Lin Ying

Study leader:

Liu Cunzhi

申请注册联系人电话:

Applicant telephone:

+86 15140133056

研究负责人电话:

Study leader's telephone:

+86 10 53912201

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

linyingbucm@163.com

研究负责人电子邮件:

Study leader's E-mail:

lcz_tg@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区北三环东路11号

研究负责人通讯地址:

北京市朝阳区北三环东路11号

Applicant address:

11 North Third Ring Road East, Chaoyang District, Beijing

Study leader's address:

11 North Third Ring Road East, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京中医药大学针灸推拿学院

Applicant's institution:

School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2020BZYLL0802

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

北京中医药大学伦理委员会

Name of the ethic committee:

Ethics Committee of Beijing University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/11/30 0:00:00

伦理委员会联系人:

秦灵灵

Contact Name of the ethic committee:

Qin Lingling

伦理委员会联系地址:

北京市朝阳区北三环东路11号

Contact Address of the ethic committee:

11 North Third Ring Road East, Chaoyang District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 53911431

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京中医药大学

Primary sponsor:

Beijing University of Chinese Medicine

研究实施负责(组长)单位地址:

北京市朝阳区北三环东路11号

Primary sponsor's address:

11 North Third Ring Road East, Chaoyang District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

朝阳区

Country:

China

Province:

Beijing

City:

Chaoyang District

单位(医院):

北京中医药大学

具体地址:

北三环东路11号

Institution
hospital:

Beijing University of Chinese Medicine

Address:

11 North Third Ring Road East

经费或物资来源:

国家重点研发计划中医药现代化研究重点专项(项目编号:2019YFC1712100)

Source(s) of funding:

National Key Research and Development Program of Traditional Chinese Medicine Modernization (Project Number: 2019YFC1712100)

研究疾病:

房颤

研究疾病代码:

Target disease:

Atrial fibrillation

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

评价针灸对于导管消融术后房颤患者生活质量的改善。

Objectives of Study:

To evaluate the effect of acupuncture on quality of life in patients with atrial fibrillation after catheter ablation.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.阵发性、持续性房颤导管消融术后(射频消融或冷冻消融); 2.年龄>=18岁,男女不限; 3.术前6个月内未接受针灸治疗者; 4.可坚持12周的治疗及后续随访。

Inclusion criteria

1.Paroxysmal or persistent AF after ablation (Radiofrequency ablation or Cryoablation); 2.Aged 18 years or above (male or female); 3.No acupuncture treatment within the previous 6 months; 4.Cooperating with 12 weeks treatment and follow-up.

排除标准:

1.严重心力衰竭(纽约心功能分级,New York Heart Association (NYHA)III级或IV级); 2.超声心动图:左心室射血分数<35%,左房直径>5.5cm; 3.有严重肺、肝、肾疾病或其它严重原发疾病; 4.皮肤对心电监测电极片过敏者。

Exclusion criteria:

1.Severe heart failure (New York Heart Association(NYHA)class III or IV); 2.Echocardiographic parameters: left ventricular ejection fraction <35%, left atrium diameter >5.5cm; 3.Severe lung, liver, kidney disease or other serious primary disease; 4.Skin allergy to ECG monitoring electrode patch.

研究实施时间:

Study execute time:

From 2021-08-02

To      2022-12-31

征募观察对象时间:

Recruiting time:

From 2021-08-02

To      2022-02-01

干预措施:

Interventions:

组别:

假针组

样本量:

73

Group:

Sham acupuncture group

Sample size:

干预措施:

针刺非经非穴,前6周每周2次,后6周每周1次

干预措施代码:

Intervention:

Acupuncture is neither meridian nor acupoint, twice a week for the first 6 weeks and once a week for the last 6 weeks

Intervention code:

组别:

针刺组

样本量:

73

Group:

Acupuncture group

Sample size:

干预措施:

针刺特定穴,前6周每周2次,后6周每周1次

干预措施代码:

Intervention:

Acupuncture at specific points was performed twice a week in the first 6 weeks and once a week in the last 6 weeks

Intervention code:

样本总量 Total sample size : 146

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大学附属医院

单位级别:

三级甲等

Institution/hospital:

Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学人民医院

单位级别:

三级甲等

Institution/hospital:

Peking University People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北

市(区县):

Country:

China

Province:

Hubei

City:

单位(医院):

武汉大学人民医院

单位级别:

三级甲等

Institution/hospital:

Renmin Hospital of Wuhan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河北

市(区县):

Country:

China

Province:

Hebei

City:

单位(医院):

河北省中医院

单位级别:

三级甲等

Institution/hospital:

Hebei Traditional Chinese Medicine Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

江苏

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

南京医科大学第一附属医院

单位级别:

三级甲等

Institution/hospital:

The First Affiliated Hospital of Nanjing Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学第三医院

单位级别:

三级甲等

Institution/hospital:

Peking University Third Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东直门医院

单位级别:

三级甲等

Institution/hospital:

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

不良事件评价

指标类型:

副作用指标

Outcome:

Adverse event evaluation

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

导管消融术后的房颤复发

指标类型:

次要指标

Outcome:

Recurrence of atrial fibrillation after ablation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率变异性

指标类型:

次要指标

Outcome:

Heart rate variability

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者因心律失常而住院的次数

指标类型:

次要指标

Outcome:

Number of hospitalizations related to arrhythmia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卫生经济学评价

指标类型:

附加指标

Outcome:

Health economic evaluation

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

导管消融术后3个月、6个月、12个月的房颤负荷

指标类型:

次要指标

Outcome:

Atrial fibrillation burden at 3, 6 and 12 months after catheter ablation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

房颤特异性生活质量量表总体评分在第3,12月较基线的变化值

指标类型:

次要指标

Outcome:

Changes in the overall score of the Atrial fibrillation Specific Quality of Life Scale from baseline at 3 and 12 months

Type:

Secondary indicator

测量时间点:

3、12月

测量方法:

Measure time point of outcome:

3 and 12 months

Measure method:

指标中文名:

AFEQT量表在症状、日常生活、治疗、满意度各维度的评分在第3,6,12月较基线的变化值

指标类型:

次要指标

Outcome:

Changes of the AFEQT subscale scores in the following 3 domains: symptoms, daily activities, and treatment concern compared to baseline at 3,6 and 12 months.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

平均心率

指标类型:

次要指标

Outcome:

Average heart rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

欧洲心律协会房颤症状评分

指标类型:

次要指标

Outcome:

Symptoms and functional capacity assessed using the modified EHRA classification system

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

SF-6D量表

指标类型:

附加指标

Outcome:

SF-6D scale

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量评价

指标类型:

主要指标

Outcome:

Evaluation of quality of life

Type:

Primary indicator

测量时间点:

第6个月

测量方法:

房颤特异性生活质量量表在第6个月总体评分较基线的变化值

Measure time point of outcome:

6 months

Measure method:

Change in the overall score of the atrial fibrillation specific quality of life scale from baseline at 6 months

指标中文名:

再次消融患者比例

指标类型:

次要指标

Outcome:

Rate of repeat catheter ablation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

导管消融术后3个月内电复律的次数

指标类型:

次要指标

Outcome:

Number of electrical cardioversion within 3 months after catheter ablation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

应用中央随机系统,进行中心分层区组随机。

Randomization Procedure (please state who generates the random number sequence and by what method):

The central random system is applied to perform central stratified area group randomization.

盲法:

对受试者、结局评价者、数据统计分析者隐藏组别信息。

Blinding:

Blind method for participants, outcome assessors and data statisticians.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内,通过中国临床试验注册中心的ResMan平台进行原始数据的共享(http://www.medresman.org.cn.)。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Raw data were shared through the ResMan platform of the China Clinical Trial Registry within 6 months after completion of the trial (http://www.medresman.org.cn.).

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

通过电子采集和管理系统记录数据。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Record data through electronic acquisition and management system.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统